Expression of microRNA-21 in Gastric Cancer of Different Tumor Stages_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 XUWen ¹ , WUWei ² , GAOMing ² , GUYi-fan ¹ ,  FEIZhe-wei ^1,2

1. Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China;
2. Department of General Surgery, Chongming Branch of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 202150, China;

Corresponding author：

FEIZhe-wei, Email: zheweifei2013@sina.cn

Keywords：

MicroRNA; MiRNA-21; Gastric cancer; TNM stage

DOI：

10.7507/1007-9424.20160341

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To quantitate expression of microRNA-21 (miRNA-21) in gastric cancer of different tumor stages and discuss its clinical value. Method The relative expressions of miRNA-21 were quantitated in the cancer tissues, corresponding normal gastric tissues adjacent to gastric cancer, and serums of 50 gastric cancer patients received opera-tion and confirmed gastric cancer by pathology and the serums of nongastric cancer patients in Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine and its Chongming Branch from January 2015 to January 2016 by real time quantitative PCR. Results The relative expression level of miRNA-21 in the gastric cancer tissues was significantly higher than that in the normal gastric tissues adjacent to gastric cancer. Among the TNM stageⅠ, Ⅱ, Ⅲ of gastric cancer patients, the relative expression levels of miRNA-21 in the cancer tissues were 2.17 (1.48-2.90), 4.08 (2.30-4.86), 8.64 (5.82-18.20), respectively and the differences among these three stages were statistically significant (P<0.05). The relative expression level of the serum miRNA-21 in the gastric cancer patients was significantly higher than that in the nongastric cancer patients, which in the serums for stageⅠ, Ⅱ, and Ⅲpatients were 31.00 (24.60-37.15), 39.10 (28.90-39.80), 44.15 (38.95-56.68), respectively and the differences among three stages were statistically significant (P<0.05). The relative expression level of miRNA-21 in the serums and cancer tissues had a positive correlation (r=0.86, P<0.05). Conclusion MiRNA-21 appears to have a potential association with TNM stage of gastric cancer, which cautiously suggests that it might be a potential indicator for prediction of preoperative TNM stage of gastric cancer.

Citation： XUWen, WUWei, GAOMing, GUYi-fan, FEIZhe-wei. Expression of microRNA-21 in Gastric Cancer of Different Tumor Stages. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(11): 1331-1334. doi: 10.7507/1007-9424.20160341 Copy

1.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin, 2015, 65(1):5-29.
2.	Wu CY, Lin JT. The changing epidemiology of Asian digestive cancers:From etiologies and incidences to preventive strategies. Best Pract Res Clin Gastroenterol, 2015, 29(6):843-853.
3.	Izuishi K, Mori H. Recent strategies for treating stage Ⅳ gastric cancer:roles of palliative gastrectomy, chemotherapy, and radiotherapy. J Gastrointestin Liver Dis, 2016, 25(1):87-94.
4.	Irani S. miRNAs signature in head and neck squamous cell carcinoma metastasis:a literature review. J Dent (Shiraz), 2016, 17(2):71-83.
5.	Asghari F, Haghnavaz N, Baradaran B, et al. Tumor suppressor microRNAs:Targeted molecules and signaling pathways in breast cancer. Biomed Pharmacother, 2016, 81:305-317.
6.	Frediani JN, Fabbri M. Essential role of miRNAs in orchestrating the biology of the tumor microenvironment. Mol Cancer, 2016, 15(1):42.
7.	Karimi Kurdistani Z, Saberi S, Tsai KW, et al. MicroRNA-21:mecha-nisms of oncogenesis and its application in diagnosis and prognosis of gastric cancer. Arch Iran Med, 2015, 18(8):524-536.
8.	Zeng Z, Wang J, Zhao L, et al. Potential role of microRNA-21 in the diagnosis of gastric cancer:a meta-analysis. PLoS One, 2013, 8(9):e73278.
9.	Marano L, Boccardi V, Braccio B, et al. Comparison of the 6th and 7th editions of the AJCC/UICC TNM staging system for gastric cancer focusing on the "N" parameter-related survival:the monoin-stitutional NodUs Italian study. World J Surg Oncol, 2015, 13:215.
10.	Xu L, Li L, Li J, et al. Overexpression of miR-1260b in non-small cell lung cancer is associated with lymph node metastasis. Aging Dis, 2015, 6(6):478-485.
11.	Shao J, Fang PH, He B, et al. Downregulated MicroRNA-133a in gastric juice as a clinicopathological biomarker for gastric cancer screening. Asian Pac J Cancer Prev, 2016, 17(5):2719-2722.
12.	Zheng D, Lin Y, Yu Y, et al. The value of preoperative neutrophil to lymphocyte ratio in indicating lymph node metastasis in patients with resectable T2 stage gastric adenocarcinoma. Clin Lab, 2016, 62(4):659-665.
13.	Schober A, Weber C, et al. Mechanisms of microRNAs in atherosc-lerosis. Annu Rev Pathol, 2016, 11:583-616.
14.	Hayward SL, Francis DM, Kholmatov P, et al. Targeted delivery of microRNA125a-5p by engineered lipid nanoparticles for the treat-ment of HER2 positive metastatic breast cancer. J Biomed Nanotechnol, 2016, 12(3):554-568.
15.	Ge Y, Zhang L, Nikolova M, et al. Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21 (^*) in SCC progression. Nat Cell Biol, 2016, 18(1):111-121.
16.	Park HK, Jo W, Choi HJ, et al. Time-course changes in the expression levels of miR-122,-155, and -21 as markers of liver cell damage, inflammation, and regeneration in acetaminophen-induced liver injury in rats. J Vet Sci, 2016,17(1):45-51.
17.	Treece AL, Duncan DL, Tang W, et al. Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns. Lab Invest, 2016, 96(6):661-671.
18.	Wu J, Li G, Wang Z, et al. Circulating microRNA-21 is a potential diagnostic biomarker in gastric cancer. Dis Markers, 2015, 2015:435656.
19.	Cui L, Zhang X, Ye G, et al. Gastric juice microRNAs as potential biomarkers for the screening of gastric cancer. Cancer, 2013, 119(9):1618-1626.
20.	Sekar D, Krishnan R, Thirugnanasambantham K, et al. Significance of microRNA 21 in gastric cancer. Clin Res Hepatol Gastroenterol, 2016, 40(5):538-545.
21.	Huang S, Wang J, Li J, et al. Serum microRNA expression profile as a diagnostic panel for gastric cancer. Jpn J Clin Oncol, 2016, 46(9):811-818.
22.	Zhu X, Lv M, Wang H, et al. Identification of circulating microRNAs as novel potential biomarkers for gastric cancer detection:a system-atic review and meta-analysis. Dig Dis Sci, 2014, 59(5):911-919.
23.	Wang Z, Cai Q, Jiang Z, et al. Prognostic role of microRNA-21 in gastric cancer:a meta-analysis. Med Sci Monit, 2014, 20:1668-1674.
24.	Wang D, Fan Z, Liu F, et al. Hsa-miR-21 and Hsa-miR-29 in tissue as potential diagnostic and prognostic biomarkers for gastric cancer. Cell Physiol Biochem, 2015, 37(4):1454-1462.
25.	Zheng Y, Cui L, Sun W, et al. MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomark, 2011-2012,10(2):71-77.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin, 2015, 65(1):5-29.
2. Wu CY, Lin JT. The changing epidemiology of Asian digestive cancers:From etiologies and incidences to preventive strategies. Best Pract Res Clin Gastroenterol, 2015, 29(6):843-853.
3. Izuishi K, Mori H. Recent strategies for treating stage Ⅳ gastric cancer:roles of palliative gastrectomy, chemotherapy, and radiotherapy. J Gastrointestin Liver Dis, 2016, 25(1):87-94.
4. Irani S. miRNAs signature in head and neck squamous cell carcinoma metastasis:a literature review. J Dent (Shiraz), 2016, 17(2):71-83.
5. Asghari F, Haghnavaz N, Baradaran B, et al. Tumor suppressor microRNAs:Targeted molecules and signaling pathways in breast cancer. Biomed Pharmacother, 2016, 81:305-317.
6. Frediani JN, Fabbri M. Essential role of miRNAs in orchestrating the biology of the tumor microenvironment. Mol Cancer, 2016, 15(1):42.
7. Karimi Kurdistani Z, Saberi S, Tsai KW, et al. MicroRNA-21:mecha-nisms of oncogenesis and its application in diagnosis and prognosis of gastric cancer. Arch Iran Med, 2015, 18(8):524-536.
8. Zeng Z, Wang J, Zhao L, et al. Potential role of microRNA-21 in the diagnosis of gastric cancer:a meta-analysis. PLoS One, 2013, 8(9):e73278.
9. Marano L, Boccardi V, Braccio B, et al. Comparison of the 6th and 7th editions of the AJCC/UICC TNM staging system for gastric cancer focusing on the "N" parameter-related survival:the monoin-stitutional NodUs Italian study. World J Surg Oncol, 2015, 13:215.
10. Xu L, Li L, Li J, et al. Overexpression of miR-1260b in non-small cell lung cancer is associated with lymph node metastasis. Aging Dis, 2015, 6(6):478-485.
11. Shao J, Fang PH, He B, et al. Downregulated MicroRNA-133a in gastric juice as a clinicopathological biomarker for gastric cancer screening. Asian Pac J Cancer Prev, 2016, 17(5):2719-2722.
12. Zheng D, Lin Y, Yu Y, et al. The value of preoperative neutrophil to lymphocyte ratio in indicating lymph node metastasis in patients with resectable T2 stage gastric adenocarcinoma. Clin Lab, 2016, 62(4):659-665.
13. Schober A, Weber C, et al. Mechanisms of microRNAs in atherosc-lerosis. Annu Rev Pathol, 2016, 11:583-616.
14. Hayward SL, Francis DM, Kholmatov P, et al. Targeted delivery of microRNA125a-5p by engineered lipid nanoparticles for the treat-ment of HER2 positive metastatic breast cancer. J Biomed Nanotechnol, 2016, 12(3):554-568.
15. Ge Y, Zhang L, Nikolova M, et al. Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21 (^*) in SCC progression. Nat Cell Biol, 2016, 18(1):111-121.
16. Park HK, Jo W, Choi HJ, et al. Time-course changes in the expression levels of miR-122,-155, and -21 as markers of liver cell damage, inflammation, and regeneration in acetaminophen-induced liver injury in rats. J Vet Sci, 2016,17(1):45-51.
17. Treece AL, Duncan DL, Tang W, et al. Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns. Lab Invest, 2016, 96(6):661-671.
18. Wu J, Li G, Wang Z, et al. Circulating microRNA-21 is a potential diagnostic biomarker in gastric cancer. Dis Markers, 2015, 2015:435656.
19. Cui L, Zhang X, Ye G, et al. Gastric juice microRNAs as potential biomarkers for the screening of gastric cancer. Cancer, 2013, 119(9):1618-1626.
20. Sekar D, Krishnan R, Thirugnanasambantham K, et al. Significance of microRNA 21 in gastric cancer. Clin Res Hepatol Gastroenterol, 2016, 40(5):538-545.
21. Huang S, Wang J, Li J, et al. Serum microRNA expression profile as a diagnostic panel for gastric cancer. Jpn J Clin Oncol, 2016, 46(9):811-818.
22. Zhu X, Lv M, Wang H, et al. Identification of circulating microRNAs as novel potential biomarkers for gastric cancer detection:a system-atic review and meta-analysis. Dig Dis Sci, 2014, 59(5):911-919.
23. Wang Z, Cai Q, Jiang Z, et al. Prognostic role of microRNA-21 in gastric cancer:a meta-analysis. Med Sci Monit, 2014, 20:1668-1674.
24. Wang D, Fan Z, Liu F, et al. Hsa-miR-21 and Hsa-miR-29 in tissue as potential diagnostic and prognostic biomarkers for gastric cancer. Cell Physiol Biochem, 2015, 37(4):1454-1462.
25. Zheng Y, Cui L, Sun W, et al. MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomark, 2011-2012,10(2):71-77.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression of microRNA-21 in Gastric Cancer of Different Tumor Stages

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content